trending Market Intelligence /marketintelligence/en/news-insights/trending/i9ajg88zdrhsc1ddkzcizw2 content esgSubNav
In This List

Sesen Bio president/CEO steps down; replacement named

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Sesen Bio president/CEO steps down; replacement named

Cambridge, Mass.-based Sesen Bio Inc. said President and CEO Stephen Hurly left the company on Aug. 7.

The board appointed Thomas Cannell to serve as president, CEO and as a class I director.

Cannell served as executive vice president, COO and president of global commercial products at Orexigen Therapeutics Inc. from June 2016 to July 2018. Cannell worked at Merck & Co. Inc. for 27 years, in sales and marketing and as a general manager. His most recent position at Merck was head of global human health operating model team.

Further, Abbie Celniker and Paul Chaney resigned from the board. Their resignations were not due to any disagreement with the company.

With Cannell's appointment to the board and the resignations of Celniker and Chaney, Sesen Bio's board was reduced to seven members from eight.

Sesen Bio develops therapies for patients with cancer.